Intellia Therapeutics
NTLA
148 hedge funds and large institutions have $582M invested in Intellia Therapeutics in 2019 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 49 increasing their positions, 29 reducing their positions, and 19 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 29
38% more call options, than puts
Call options by funds: $3.31M | Put options by funds: $2.4M
37% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 19
35% more capital invested
Capital invested by funds: $430M → $582M (+$151M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
5% more funds holding
Funds holding: 141 → 148 (+7)
2.59% more ownership
Funds ownership: 72.6% → 75.19% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$17.6M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$15.9M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$15.6M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.41M |
| 5 |
BlackRock
New York
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.64M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8M |
| 3 |
Morgan Stanley
New York
|
-$3.99M |
| 4 |
Citigroup
New York
|
-$3.57M |
| 5 |
Renaissance Technologies
New York
|
-$3.11M |
NTLA Hedge Fund Activity: Q1 2019 in Review
148 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2019, worth a combined $582M — up 35% from $430M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new NTLA positions and 19 closed out — a net gain of 7 holders — while 49 added to existing stakes and 29 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $17.6M. The largest seller was Deutsche Bank, cutting an estimated $8.64M.
- 148 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2019, up from 141 in Q4 2018.
- Funds reported $582M of Intellia Therapeutics stock for Q1 2019, up 35% quarter-over-quarter.
- 26 funds opened new Intellia Therapeutics positions in Q1 2019 and 19 closed out, a net change of +7 holders.
- The largest Intellia Therapeutics buyer in Q1 2019 was ARK Investment Management, an estimated $17.6M added.
- The largest Intellia Therapeutics seller in Q1 2019 was Deutsche Bank, an estimated $8.64M sold.
Based on aggregated 13F filings for Q1 2019.